Update on prospective markers of treatment response with omalizumab in chronic spontaneous urticaria

• DOI: 10.26416/aler.7.2.2023.8194
• Publication Date: 2023-07-05T07:30:07Z
• Authors: Sabina-Loredana C...; Roxana Silvia Bum...; Selda Ali; Oana-Andreia Coman
• Keywords: Omalizumab; Guideline; Ciclosporin

Chronic spontaneous urticaria (CSU) is the most common form of chronic urticaria, frequently evaluated in allergology and dermatology services, with an increasing incidence, evolution usually several years often incompletely controlled by treatment, strongly impacting patient's quality life. The current therapeutic algorithm recommended international guideline, although useful, not perfect, given fact that it based on a one-size-fits-all approach for all CSU patients: initially, second-generation antihistamines are administered up to maximum dose, case insufficient control, omalizumab added and, last step ciclosporin. Ideally, treatment patients should be individualized predictors response each type avoid less effective options. In recent years, potential clinical laboratory parameters have been described could predict three guideline-recommended lines management CSU. Low level total IgE correlated nonresponse has best evidence omalizumab. Further prospective randomized studies needed confirm and/or identify other response.